Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Autocrine lysophosphatidic acid signaling activates β-catenin and promotes lung allograft fibrosis
Pengxiu Cao, Yoshiro Aoki, Linda Badri, Natalie M. Walker, Casey M. Manning, Amir Lagstein, Eric R. Fearon, Vibha N. Lama
Pengxiu Cao, Yoshiro Aoki, Linda Badri, Natalie M. Walker, Casey M. Manning, Amir Lagstein, Eric R. Fearon, Vibha N. Lama
View: Text | PDF
Research Article Cell biology

Autocrine lysophosphatidic acid signaling activates β-catenin and promotes lung allograft fibrosis

  • Text
  • PDF
Abstract

Tissue fibrosis is the primary cause of long-term graft failure after organ transplantation. In lung allografts, progressive terminal airway fibrosis leads to an irreversible decline in lung function termed bronchiolitis obliterans syndrome (BOS). Here, we have identified an autocrine pathway linking nuclear factor of activated T cells 2 (NFAT1), autotaxin (ATX), lysophosphatidic acid (LPA), and β-catenin that contributes to progression of fibrosis in lung allografts. Mesenchymal cells (MCs) derived from fibrotic lung allografts (BOS MCs) demonstrated constitutive nuclear β-catenin expression that was dependent on autocrine ATX secretion and LPA signaling. We found that NFAT1 upstream of ATX regulated expression of ATX as well as β-catenin. Silencing NFAT1 in BOS MCs suppressed ATX expression, and sustained overexpression of NFAT1 increased ATX expression and activity in non-fibrotic MCs. LPA signaling induced NFAT1 nuclear translocation, suggesting that autocrine LPA synthesis promotes NFAT1 transcriptional activation and ATX secretion in a positive feedback loop. In an in vivo mouse orthotopic lung transplant model of BOS, antagonism of the LPA receptor (LPA1) or ATX inhibition decreased allograft fibrosis and was associated with lower active β-catenin and dephosphorylated NFAT1 expression. Lung allografts from β-catenin reporter mice demonstrated reduced β-catenin transcriptional activation in the presence of LPA1 antagonist, confirming an in vivo role for LPA signaling in β-catenin activation.

Authors

Pengxiu Cao, Yoshiro Aoki, Linda Badri, Natalie M. Walker, Casey M. Manning, Amir Lagstein, Eric R. Fearon, Vibha N. Lama

×

Figure 4

In vivo fibrotic behavior of human BOS MCs after adoptive transfer demonstrates dependence on intact ATX/LPA1 signaling.

Options: View larger image (or click on image) Download as PowerPoint
In vivo fibrotic behavior of human BOS MCs after adoptive transfer demon...
(A) BOS MCs establish fibrotic lesions in vivo after adaptive transfer. MCs obtained from normal and fibrotic human lung allograft (non-BOS MCs and BOS MCs) were infected with DsRed lentivirus and adoptively transferred via intratracheal administration into lungs of immunodeficient (Beige/Nude/XID) mice. Lungs were harvested on day 45 after administration of cells and stained with DAPI. Lower panel shows quantitative analysis of single cells or cell clusters (>3 adjacent cells) of human MCs in murine lung sections. Nucleated red fluorescent cells were quantitated under ×200 magnification in 12 fields per slide. Mean ± SEM with ANOVA (n = 4 for non-BOS MCs and 10 for BOS MCs). Scale bars: 50 μm. (B) Confocal microscopy demonstrating interstitial localization of human BOS MCs engrafted in immunodeficient mouse lungs. Epithelia were stained green by cytokeratin immunofluorescence staining (MAB3412, Millipore). Images of z-projections from two different rotation angles are shown. (C) Trichrome staining images of immunodeficient mouse lungs intratracheally transferred with non-BOS or BOS MCs. Scale bars: 20 μm. (D) Characterization of fibrotic lesions induced by adoptive transfer of BOS MCs into immunodeficient mouse lungs. Positive immunofluorescence staining with α-SMA antibody (M0851, Dako) was noted in DsRed fluorescent human BOS MC clusters. Scale bars: 50 μm. (E) Endogenous LPA synthesis and signaling are requisite for establishing fibrotic lesions of BO MCs after adoptive transfer. DsRed-labeled BOS MCs were infected with lentivirus containing the silencing control vector, LPA1 shRNA, or ATX shRNA and then were adoptively transferred into immunodeficient mice. BOS MCs infected with LPA1 or ATX shRNA–expressing lentivirus failed to form fibrotic lesions. Right panel shows quantitative analysis. Mean ± SEM (n = 3/group with ANOVA). Scale bars: 50 μm. ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts